Regencell Bioscience Holdings Limited Included in the MSCI World Micro Cap Index
Regencell Bioscience Holdings Limited (NASDAQ: RGC) announced the addition of its shares to the MSCI World Micro Cap Index effective December 1, 2021. This decision, made public on November 11, 2021, reflects Regencell's growing recognition within the investment community. The MSCI World Micro Cap Index includes 6,192 constituents and covers around 1% of the free float-adjusted market capitalization across 23 developed countries. CEO Yat-Gai Au expressed optimism that this milestone will boost the company's visibility among institutional investors.
- Inclusion in the MSCI World Micro Cap Index may enhance investor visibility.
- The MSCI index covers micro-cap representation across 23 developed countries.
- None.
MSCI Inc., a leading provider of research-based indexes and analytics, announced Regencell’s addition on
Mr.
About
Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements. Such forward-looking statements include the business plan of the joint venture, objectives, expectations and intentions of the joint venture parties, and Regencell’s estimated and future results of operations, business strategies, competitive position, industry environment and potential growth opportunities. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, our actual results may differ materially from our expectations or projections. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: there is uncertainty about the spread of the COVID-19 virus and the impact it will have on expected operations of the joint venture, the demand for the planned COVID TCM treatments. These and other risks and uncertainties are detailed in the other public filings with the
Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20211122006060/en/
For more information:
Corporate:
COO & CSO
ir@rgcbio.com
Investors outside of
Vice President
(212) 836-9611
lcati@equityny.com
Investors in
SPRG_Regencell@sprg.com.hk
Source:
FAQ
When will Regencell Bioscience Holdings Limited be added to the MSCI World Micro Cap Index?
What does the inclusion in the MSCI World Micro Cap Index mean for RGC?
How many constituents are in the MSCI World Micro Cap Index?